Becton Dickinson (NYSE:BDX) announced a quarterly dividend on Monday, April 23rd, RTT News reports. Stockholders of record on Friday, June 8th will be paid a dividend of 0.75 per share by the medical instruments supplier on Friday, June 29th. This represents a $3.00 annualized dividend and a dividend yield of 1.29%.
Becton Dickinson has raised its dividend by an average of 9.6% per year over the last three years and has increased its dividend annually for the last 46 consecutive years. Becton Dickinson has a payout ratio of 28.1% indicating that its dividend is sufficiently covered by earnings. Equities analysts expect Becton Dickinson to earn $12.63 per share next year, which means the company should continue to be able to cover its $3.00 annual dividend with an expected future payout ratio of 23.8%.
Shares of NYSE:BDX traded up $0.14 during trading on Monday, hitting $233.02. 721,490 shares of the stock were exchanged, compared to its average volume of 1,369,584. The firm has a market capitalization of $62,002.55, a price-to-earnings ratio of 24.58, a price-to-earnings-growth ratio of 1.69 and a beta of 1.15. The company has a debt-to-equity ratio of 1.04, a current ratio of 1.54 and a quick ratio of 0.93. Becton Dickinson has a 12-month low of $175.66 and a 12-month high of $248.39.
In other Becton Dickinson news, Director Timothy M. Ring sold 269,661 shares of the business’s stock in a transaction on Thursday, February 8th. The stock was sold at an average price of $217.82, for a total value of $58,737,559.02. Following the completion of the transaction, the director now directly owns 295,753 shares in the company, valued at approximately $64,420,918.46. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Timothy M. Ring sold 176 shares of the business’s stock in a transaction on Friday, February 23rd. The shares were sold at an average price of $218.27, for a total value of $38,415.52. Following the completion of the transaction, the director now owns 170,688 shares of the company’s stock, valued at $37,256,069.76. The disclosure for this sale can be found here. Insiders sold a total of 281,108 shares of company stock valued at $61,321,396 over the last quarter. 1.00% of the stock is currently owned by insiders.
A number of equities research analysts recently issued reports on BDX shares. KeyCorp started coverage on Becton Dickinson in a research note on Friday, January 5th. They issued an “overweight” rating and a $260.00 target price on the stock. Citigroup raised Becton Dickinson from a “neutral” rating to a “buy” rating and upped their target price for the company from $237.00 to $251.00 in a research note on Tuesday, April 10th. Bank of America reaffirmed a “buy” rating and issued a $260.00 target price on shares of Becton Dickinson in a research note on Friday, January 19th. Deutsche Bank set a $260.00 target price on Becton Dickinson and gave the company a “buy” rating in a research note on Friday, December 29th. Finally, Evercore ISI started coverage on Becton Dickinson in a research note on Wednesday, January 3rd. They issued an “outperform” rating and a $245.00 target price on the stock. Five equities research analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $241.19.
TRADEMARK VIOLATION WARNING: “Becton Dickinson Declares Quarterly Dividend of $0.75 (BDX)” was originally posted by StockNewsTimes and is owned by of StockNewsTimes. If you are accessing this piece on another domain, it was stolen and republished in violation of United States and international copyright laws. The correct version of this piece can be viewed at https://stocknewstimes.com/2018/04/23/becton-dickinson-declares-quarterly-dividend-of-0-75-bdx.html.
About Becton Dickinson
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. It operates in two segments, BD Medical and BD Life Sciences. The BD Medical segment offers syringes, pen needles, and other products for diabetes; needles, syringes, and intravenous catheters for medication delivery; prefilled IV flush syringes; regional anesthesia needles and trays; sharps disposal containers; closed-system transfer devices; skin antiseptic products; surgical and laparoscopic instrumentations; intravenous medication safety and infusion therapy delivery, and automated medication dispensing and supply management systems; medication inventory optimization and tracking systems; and prefillable drug delivery systems.
Receive News & Ratings for Becton Dickinson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and related companies with MarketBeat.com's FREE daily email newsletter.